A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

← catalyst calendar

NCT05536141 · readout ≤ 955 d

Sponsored by Arcus Biosciences, Inc. (industry) · RCUS — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

362estimated

Sites

Countries

Australia, South Korea, Spain +1

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2022-10-26

actual

When the study began enrolling

Primary completion

Mar 2029

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Mar 2029

estimated

The whole study's end, after follow-up

First posted

2022-09-10

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-29

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Clear Cell Renal Cell Carcinoma
Solid Tumors

Interventions

Drug: casdatifan — also filed as AB521
Drug: Cabozantinib
Drug: Zimberelimab — also filed as AB122
Drug: Ipilimumab

Primary outcomes

what the primary-completion date above is the date OF

Number of participants with dose limiting toxicities (DLTs)

measured Up to 4 months

Number of participants with adverse events (AEs)

measured Up to 4 months

Permalink · RCUS's whole pipeline · Catalyst calendar · Every registered study · What changed